In a joint letter, sent to every NHS trust, they say that now there is less workforce pressure it should be the default position to offer every patient enrolment into a trial, with a target of recruiting 60% of eligible patients.
The RECOVERY trial has already shown that dexamethasone cuts deaths by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients receiving oxygen, which has “informed clinical practice worldwide and was down to your efforts in facilitating research in the NHS,” the CMOs note…
